X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Change in Account Payables of $642000.0 for Q4 2025, up 124.19% on a QoQ basis from -$2.7 million in Q3 2025, and up 723.08% year-over-year from $78000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Change in Account Payables (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Change in Account Payables history runs 9 years deep, the most recent figure standing at $642000.0 for Q4 2025.
- Quarterly Change in Account Payables rose 723.08% year-over-year to $642000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 million (down 941.61% YoY) and the FY2025 annual result came in at -$3.0 million, down 941.61% from the prior year.
- Change in Account Payables was $642000.0 for Q4 2025 at X4 Pharmaceuticals, up from -$2.7 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.9 million in Q4 2022 and bottomed at -$3.4 million in Q2 2025.
- A 5-year average of $128000.0 and a median of $41000.0 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 3000.0% — and 2025, when it soared 61800.0%.
- X4 Pharmaceuticals' Change in Account Payables stood at $1.9 million in 2021, then jumped by 109.89% to $3.9 million in 2022, then plunged by 79.31% to $808000.0 in 2023, then slumped by 90.35% to $78000.0 in 2024, then surged by 723.08% to $642000.0 in 2025.
- Business Quant data shows XFOR's Change in Account Payables at $642000.0 in Q4 2025, -$2.7 million in Q3 2025, and -$3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | - |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn | 642,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 642,000.00 |
| Dec 31, 2025 | 642,000.00 |
| Sep 30, 2025 | -2.65 Mn |
| Sep 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 78,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Sep 30, 2024 | 580,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Jun 30, 2024 | -948,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Dec 31, 2023 | 808,000.00 |
| Sep 30, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.24 Mn |